Takeda's diabetes pipeline moves forward as first-in-class GPR40 agonist enters Phase III
This article was originally published in Scrip
Executive Summary
Takeda has moved another step closer to filling at least part of the looming revenue gap from the upcoming loss of exclusivity for its top product Actos (pioglitazone) with the start of a late-stage development programme for a novel oral antidiabetic.